NeuroVigil Receives More in First Round Funding Than Facebook and Google Combined
NeuroVigil is the company behind iBrain, a miniaturized EEG system which detects the impact of drugs on the brain in patients with neurological diseases, and use unusual brain signals as potential biomarkers associated with harmful side effects. NeuroVigil describes itself as a neurotechnology company centered on a “fundamentally new way to assess brain activity, non-invasively, and rapidly, using a single channel of electroencephalogram.”
The company recently got its first round of funding from a mysterious “anonymous” person. The amount of cash is bigger than Google’s and Facebook’s first round investments combined.
Imagine the money that could be made by a drug company that accurately predicted and treated the onset of Alzheimer’s before any symptoms surfaced. That explains why NeuroVigil, a company specializing in non-invasive, wireless brain-recording tech, just got a cash injection that puts it at a valuation “twice the combined seed valuations of Google’s and Facebook’s first rounds,” according to a company announcement. The round was led by an anonymous American industrialist and technology visionary, with participants distributed across both the U.S. West and East Coasts.